Melanoma News and Research

Latest Melanoma News and Research

Scientists demonstrate the importance of RNA editing in melanoma development

The importance of RNA editing in melanoma has been demonstrated by scientists at The University of Texas MD Anderson Cancer Center. The study revealed that a lack of RNA editing, a process by which information inside RNA molecules is transformed, leads to tumor growth and progression through manipulation of proteins.

17 Feb 2015

Changes in moles and skin cancer: an interview with Dr Anjali Mahto, Consultant Dermatologist & British Skin Foundation Spokesperson

Melanoma is the 5th most common cancer in the UK and its incidence is continuing to increase since the mid-1970s. Cancer Research UK reports that its rates have increased more rapidly than any of the current ten most common cancers in males and females. Whilst some of this may be attributed to better surveillance and earlier detection, the real problem lies with sun-seeking behaviour and exposure to ultraviolet (UV) radiation.

16 Feb 2015

Moffitt physicians promote novel screening strategies to decrease melanoma mortality

Melanoma, the most deadly type of skin cancer, was to blame for approximately 9,700 deaths in 2014. And with the number of melanoma cases increasing each year, it is believed that the disease could become one of the most common types of cancer in the United States by 2030. Promoting and developing national screening strategies may help to reduce deaths due to melanoma.

16 Feb 2015

New laser technology shows promise for cancer treatment

Surgeons rely on 200-year-old technology when removing cancer--sight and touch--to determine how much to remove and what to leave alone. Laser technology pioneered at Florida Atlantic University has the promise to help a surgeon better determine if an area is cancer or healthy tissue. Moreover, when combined with laser treatment for cancer, this work lays the groundwork for laser robotic treatment of cancer.

16 Feb 2015

Researchers identify two cell-signaling molecules that appear critical to stalling cancer's spread

In what is believed to be the largest epigenetic analysis to date of cell-signaling molecules in early-stage melanoma, researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center have identified two tiny bits of non-coding genetic material in primary tumors that appear critical to stalling the cancer's spread -- and essentially setting the biological fate of the disease.

15 Feb 2015

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Amgen announced today that the Cellular, Tissue and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec.

11 Feb 2015

Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease among men and women in Germany. So-called microsatellite stable colorectal cancer with mutations in the BRAF gene represents a particularly aggressive form.

11 Feb 2015

Combination therapies may overcome resistance to targeted cancer drugs

A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.

10 Feb 2015

Study shows that text messages could improve skin cancer prevention, promote sun protection

Australians' love affair with mobile phones could save their life according to a joint QUT, Cancer Council Queensland and University of Queensland study using text messages to improve skin cancer prevention and promote sun protection.

6 Feb 2015

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapies addressing high-unmet medical needs, today announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone with Hapten Pharmaceuticals, LLC.

5 Feb 2015

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company's drug candidate CF101 have completed the study's 32 week treatment protocol.

4 Feb 2015

Researchers suggest novel concept for developing vaccines against HIV and cancer

A experimental trial has shown successful by inducing serum in mice and has been highly neutralizing towards those ailments.

4 Feb 2015

ESMO highlights collaborative efforts to improve access to cancer medicines

On World Cancer Day 2015, ESMO acknowledges patient's right to access treatment and highlights collaborative efforts towards improving access for all.

4 Feb 2015

New app for clinical detection of skin cancer launched on World Cancer Day

On World Cancer Day 2015, general practitioners, physicians and dermatologists in the United States, United Kingdom and Australia are being asked for their feedback during the advanced trial phase of a new, free app that has the potential to play a vital role in the clinical detection of skin cancer.

4 Feb 2015

Professional medical societies must update guidelines for Googling patients, say Penn researchers

With the Internet and social media becoming woven into the modern medical practice, Penn State College of Medicine researchers contend that professional medical societies must update or amend their Internet guidelines to address when it is ethical to "Google" a patient.

3 Feb 2015

Scientists identify gene mutations that provide better insight into hepatitis-liver cancer link

Using whole genomic sequencing, scientists from RIKEN in Japan have for the first time demonstrated the profound effect that chronic hepatitis infection and inflammation can have on the genetic mutations found in tumors of the liver, potentially paving the way to a better understanding of the mechanisms through which these chronic infections can lead to cancer.

2 Feb 2015

Immunotherapy expert discusses the concept of precision immunology and personalized medicine

With President Obama's recent State of the Union speech addressing the launch of a national precision medicine initiative to further tackle cancer and other diseases, a leading immunotherapy expert from Rutgers Cancer Institute of New Jersey weighs in on where we stand with precision immunology and personalized medicine and what needs to be accomplished.

30 Jan 2015

HCI researchers find cell mechanism that may trigger pancreatic cancer

Researchers at Huntsman Cancer Institute at the University of Utah have found that defects in how cells are squeezed out of overcrowded tissue to die, a process called extrusion, may be a mechanism by which pancreatic cancer begins. From these findings, they may have identified an effective way to reverse the defective extrusion's effects without destroying normal tissues nearby.

28 Jan 2015

Yale researcher receives 2015 Frontiers of Knowledge Award in Biomedicine

A Spanish foundation has awarded a major scientific prize to Yale researcher Joseph Schlessinger and two colleagues in recognition of their work leading to the first personalized treatments for cancer. The 2015 Frontiers of Knowledge Award in Biomedicine from the Madrid-based BBVA Foundation includes a €400,000 cash prize.

27 Jan 2015

Researchers reveal role of epigenetic factors in malignant skin cancer

Melanoma, the most aggressive of all skin cancer strains, is often fatal for patients due to the pronounced formation of metastases. Until now, a melanoma's rampant growth was mainly attributed to genetic causes, such as mutations in certain genes. However, researchers from the University of Zurich now reveal that so-called epigenetic factors play a role in the formation of metastases in malignant skin cancer. This opens up new possibilities for future cancer treatments.

22 Jan 2015

Melanoma News and Research

Latest Melanoma News and Research

Scientists demonstrate the importance of RNA editing in melanoma development

Changes in moles and skin cancer: an interview with Dr Anjali Mahto, Consultant Dermatologist & British Skin Foundation Spokesperson

Moffitt physicians promote novel screening strategies to decrease melanoma mortality

New laser technology shows promise for cancer treatment

Researchers identify two cell-signaling molecules that appear critical to stalling cancer's spread

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Freiburg researchers identify novel approach to inhibit signalling processes in colorectal cancer cells

Combination therapies may overcome resistance to targeted cancer drugs

Study shows that text messages could improve skin cancer prevention, promote sun protection

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Researchers suggest novel concept for developing vaccines against HIV and cancer

ESMO highlights collaborative efforts to improve access to cancer medicines

New app for clinical detection of skin cancer launched on World Cancer Day

Professional medical societies must update guidelines for Googling patients, say Penn researchers

Scientists identify gene mutations that provide better insight into hepatitis-liver cancer link

Immunotherapy expert discusses the concept of precision immunology and personalized medicine

HCI researchers find cell mechanism that may trigger pancreatic cancer

Yale researcher receives 2015 Frontiers of Knowledge Award in Biomedicine

Researchers reveal role of epigenetic factors in malignant skin cancer

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in